Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

March 13, 2018 by Website Admin in

Bellicum today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs).

Tweet

Share

Pin it

Previous StoryLivaNova Enters into Definitive Agreement to Divest Its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation Next StoryProxima Aims to Fill CRO Gap for Houston’s Growing Biotech Community